Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
复制标题
DOI：
10.1158/2159-8290.cd-20-0596
复制
发表时间：
2020-08-01
期刊：
影响因子：
28.2
通讯作者：
Hellmann, Matthew D.
中科院分区：
文献类型：
--
作者：
Luo, Jia;Rizvi, Hira;Hellmann, Matthew D.
2019冠状病毒病（COVID-19）大流行导致肿瘤学实践发生了巨大变化。目前尚不清楚程序性死亡1（PD-1）阻断治疗是否会影响癌症患者COVID-19的疾病严重程度。为了解决这一不确定性，我们检查了被诊断患有COVID-19的连续肺癌患者，并在没有或之前接受PD-1阻断的基础上检查了严重程度。总体而言，肺癌患者的COVID-19严重程度较高，包括超过一半的患者需要住院治疗，近四分之一的患者死亡。正如预期的那样，既往PD-1阻断与吸烟状态相关。在调整吸烟状况后，PD-1阻断剂暴露与COVID-19严重程度风险增加无关。PD-1阻断剂似乎不会影响肺癌患者的COVID-19严重程度。意义：在COVID-19大流行期间，肿瘤学实践中的一个关键问题是PD-1阻断剂治疗是否会影响COVID-19的严重程度。我们对肺癌患者的分析支持PD-1阻断治疗的安全性，以实现最佳的癌症结局。
The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade therapy affects severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity on the basis of no or prior receipt of PD-1 blockade. Overall, the severity of COVID-19 in patients with lung cancer was high, including need for hospitalization in more than half of patients and death in nearly a quarter. Prior PD-1 blockade was, as expected, associated with smoking status. After adjustment for smoking status, PD-1 blockade exposure was not associated with increased risk of severity of COVID-19. PD-1 blockade does not appear to affect the severity of COVID-19 in patients with lung cancers.SIGNIFICANCE: A key question in oncology practice amidst the COVID-19 pandemic is whether PD-1 blockade therapy affects COVID-19 severity. Our analysis of patients with lung cancers supports the safety of PD-1 blockade treatment to achieve optimal cancer outcomes.